Pfizer: Omicron booster strong against BQ.1.1

Friday, 18. November 2022 14:36

Pfizer Inc. and BioNTech SE announced on Friday that their bivalent jab aimed at the Omicron strain of COVID-19 shows a higher success rate against the emerging sub-variant BQ.1.1 in older people compared to the original vaccine produced by the partnership.

According to data published on the online archive bioRxiv, antibody levels against the variant increased nearly nine-fold in the population aged 55 and above who received the Omicron jab, compared to a roughly double increase in participants who received the initial shot.

Pfizer recently declared that a new, single-dose vaccine providing combined protection against Omicron and influenza is in development. Earlier this month, United Kingdom Medicines and Healthcare products Regulatory Agency approved the company's bivalent booster for citizens older than 12.

Related Links: BioNTech SEPfizer Inc.
Baha Breaking News (BBN) / MX